NSTK · 01.2026Independent supplement reference
NutriStack
Edition 1.0Updated July 13, 2026

Ranolazine

Prescription ·Exploratory record · not publication-reviewed ·Updated July 13, 2026

Ranolazine is a unique anti-anginal agent that works by inhibiting the late sodium current without significant hemodynamic effects. Unlike other anti-anginals, it does not significantly reduce heart rate or blood pressure, making it suitable as add-on therapy for chronic stable angina when conventional agents are inadequate.

Evidence tier
Moderate
Indexed sources
10 2017–2023
Interactions
0
Category
Prescription
Read the sources → Compare profiles
Publication status

Exploratory record, not a reviewed medical publication.

See the editorial and medical-review policies for the publication gate.

This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.

In short

What the research says.

A quick, data-only summary. The full evidence, dosing, and sources are below.

Ranolazine is a unique anti-anginal agent that works by inhibiting the late sodium current without significant hemodynamic effects. NutriStack rates the supporting evidence as moderate. Common adult dosing is 500 mg twice daily, titrated up to 1000 mg twice daily (as prescribed by your physician), though a prescriber sets the actual dose. This profile indexes 10 sources.

What it's good for
  • Reduces angina frequency and nitroglycerin use6,2
  • No significant effect on heart rate or blood pressure1,5
  • Add-on therapy when conventional anti-anginals insufficient
  • May improve diastolic function1
  • Modest HbA1c reduction in diabetic patients
What to watch for
  • Dizziness
  • Headache
  • Nausea
  • Hepatic cirrhosis (Child-Pugh C)
  • Concurrent strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, nelfinavir, ritonavir)

The bottom line

Evidence rating moderate. Most-documented uses: reduces angina frequency and nitroglycerin use, no significant effect on heart rate or blood pressure, add-on therapy when conventional anti-anginals insufficient. 10 sources indexed (2017–2023), with 0 interaction records on file.

The science

How it works, mechanistically.

Core mechanism

Selectively inhibits the late phase of the inward sodium current (late INa) in cardiomyocytes. During ischemia, late INa is enhanced, causing intracellular sodium overload and subsequent calcium overload via the Na+/Ca2+ exchanger. Ranolazine reduces this sodium and calcium overload, improving diastolic relaxation and reducing myocardial oxygen consumption without affecting heart rate or blood pressure.

Class
Late Sodium Current Inhibitor
Dosing

Dosing & protocol.

Common range
500 mg twice daily, titrated up to 1000 mg twice daily (as prescribed by your physician)
Recommended form
Extended-release oral tablet (do not crush or chew)

Can be taken with or without food; high-fat meals increase absorption by ~20% but this is not clinically significant; CYP3A4 substrate, avoid grapefruit juice

Safety

Full safety detail.

Side effects

  • Dizziness
  • Headache
  • Nausea
  • Constipation
  • QT prolongation (modest, ~6 ms)
  • Abdominal pain
  • Dry mouth

Contraindications

  • Hepatic cirrhosis (Child-Pugh C)
  • Concurrent strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, nelfinavir, ritonavir)
  • Concurrent CYP3A4 inducers (rifampin, phenobarbital, phenytoin)
  • Pre-existing QT prolongation
Sources

Sources, by evidence tier.

Numbered references. Citations throughout the page link here.

Meta-analyses & systematic reviews

5

Reference material

5
FAQ

Common questions.

Quick answers about Ranolazine, drawn from the data on this page.

What is Ranolazine?

Ranolazine is a unique anti-anginal agent that works by inhibiting the late sodium current without significant hemodynamic effects. Unlike other anti-anginals, it does not significantly reduce heart rate or blood pressure, making it suitable as add-on therapy for chronic stable angina when conventional agents are inadequate.

What is Ranolazine used for?

Commonly cited benefits of Ranolazine include: Reduces angina frequency and nitroglycerin use; No significant effect on heart rate or blood pressure; Add-on therapy when conventional anti-anginals insufficient; May improve diastolic function; Modest HbA1c reduction in diabetic patients. NutriStack rates the overall evidence as moderate.

What is a typical dose of Ranolazine?

A typical adult dose of Ranolazine is 500 mg twice daily, titrated up to 1000 mg twice daily (as prescribed by your physician). The commonly recommended form is Extended-release oral tablet (do not crush or chew). These are general ranges, not personalized advice; confirm the right dose with a clinician.

What are the side effects of Ranolazine?

Reported side effects include dizziness, headache, nausea, constipation, qt prolongation (modest, ~6 ms), abdominal pain. This is educational information; check with a healthcare professional before use.

How strong is the evidence for Ranolazine?

NutriStack rates this as Moderate, meaning several aligned RCTs or one large RCT plus supporting reviews. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.

Use this with your stack

Ranolazine in NutriStack.

Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.

Download on the App Store → Read the methodology

NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.